21 employees
Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
2021
$16M
from 4 investors over 4 rounds
Engimmune Therapeutics raised $16M on May 3, 2022
Investors: Novo Holdings, Pureos Bioventures and Kinled Holding Ltd
Engimmune Therapeutics raised $546K on February 21, 2022
Investors: BaseLaunch